期刊文献+

LY294002对Jeko-1细胞的增殖抑制及作用机制研究 被引量:5

Antiproliferative Effects of LY294002 on MCL Jeko-1 Cell Line and Its Mechanism
下载PDF
导出
摘要 本研究旨在探讨磷脂酰肌醇3-激酶/丝氨酸苏氨酸激酶(PI3K/Akt)特异性抑制剂LY294002对人套细胞淋巴瘤Jeko-1细胞生长、细胞凋亡的影响及其作用机制。四甲基偶氮唑盐(MTT)方法检测细胞增殖率;流式细胞术检测细胞凋亡水平;Western blot检测凋亡相关蛋白Cyclin D1、Bcl-2、procaspase-3及PI3K/Akt信号通路相关蛋白p-Akt、p-mTOR、p-P70S6K的变化。结果表明,LY294002能抑制Jeko-1细胞的增殖。Jeko-1细胞经LY294002 0、5、10和20μmol/L作用24 h后,凋亡率分别为(3.25±1.27)%、(11.34±2.35)%、(22.81±2.74)%和(43.61±3.48)%,差异有统计学意义(P<0.01);Western blot检测发现,凋亡相关蛋白Cyclin D1、Bcl-2、procaspase-3表达下降,PI3K/Akt信号通路相关蛋白p-Akt、p-mTOR、p-P70S6K磷酸化水平降低。结论:LY294002可明显抑制Jeko-1细胞增殖,其机制可能通过下调PI3K/Akt信号通路中的p-Akt、p-mTOR、p-P70S6K磷酸化水平,抑制PI3K/Akt信号通路,促进细胞凋亡。 This study was aimed to investigate the effects of LY294002, a specific inhibitor of phosphatidylinositol 3- kinase, on growth and apoptosis of MCL Jeko-1 cell line and its mechanism. The proliferation inhibitory rate of Jeko-1 cells treated by different doses of LY294002 was assayed by MTT method; the level of apoptosis of Jeko-1 cells was dctected by flow cytometry; the expression level of apoptosis-related protein Cyclin D1, Bcl-2, procaspase-3 and PI3K/ Akt signaling pathway protein phosphorylated-Akt ( p-Akt), phosphorylated-TOR ( p-mTOR), phosphorylated-PTOS6K (p-P70S6K) phosphorylated-Akt (p-Akt) in Jeko-1 cells were determined by Western blot. The results showed that the growth of Jeko-1 cell line was inhibited by LY294002. The apoptosis rates of Jeko-1 cells treated with 0,5,10 and 20 ixmo1/LofLY294002 for 24 hours were (3.25 ± 1.27)%, (11.34 ± 2.35)%, (22.81 ±2.74)%, (43.61 ± 3.48) % respectively, the difference between them was statistically significant (P 〈 0.01 ). Phosphorylation levels of PI3K/Akt signaling pathway protein p-AM, p-mTOR, p-PTOS6K decreased, the expression of apoptosis-related protein cyclin D1, Bcl-2, procaspase-3 was down-regulated. It is concluded that the LY294002 can inhibit Jeko-1 cell proliferation, which may be realized through down-regulating the phosphorylation level of p-Akt, p-mTOR, p-PTOS6K, inhibiting the P13k/Akt signaling pathway, and promoting the cell apoptosis.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2013年第5期1183-1186,共4页 Journal of Experimental Hematology
关键词 LY294002 磷脂酰肌醇3-激酶 丝氨酸苏氨酸激酶 套细胞淋巴瘤 细胞凋亡 LY294002 phosphatidylinositol-3-kinase/protein kinase mantle cell lymphoma apoptosis
  • 相关文献

参考文献12

  • 1Herrmann A,Hoster E,Zwingers T,et al.Improvement of over all survival in advanced stage mantle cell lymphoma.J Clin Oncol,2009;27(4):511-518.
  • 2Snehal MG,Pritha R.Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer.Am J Nucl Med Mol Imaging,2012;2(4):418-431.
  • 3Jayashree K,Amit M.PI3K/AKT/mTOR Pathway in Angiogenesis.Front Mol Neurosci,2011 ;4 (51):1-8.
  • 4Kong D,Yamori T.Phosphatidylinositol 3-kinase inhibitors:promising drug candidates for cancer therapy.Cancer Sci,2008;99(9):1734-1740.
  • 5Jaclyn L,Gideon MB,Wendy BB,et al.Targeting the PI3K/Akt/mTOR pathway:effective combinations and clinical considerations.Drug Resist Updat,2008;11(12):32-50.
  • 6Knowles MA,Platt FM,Ross RL,et al.Phosphatidylinositol 3kinase (PI3K) pathway activation in bladder cancer.Cancer Metastasis Rev,2009;28(34):305-316.
  • 7Liu P,Cheng H,Roberts TM,Zhao JJ.Targeting the phosphoinositide 3-kinase pathway in cancer.Nat Rev Drug Discov,2009 ;8(8) ;627-644.
  • 8Courtney KD,Corcoran RB,Engelman JA,et al.The PI3K pathway as drug target in human cancer.J Clin Oncol,2010 ;28 (6):1075-1083.
  • 9Carvalho S,Schmitt F.Potential role of PI3Kinhibitors in the treatment of breast cance.Future Oncol,2010; 6.(8):1251-1263.
  • 10Wen PY,Lee EQ,Reardon DA,et al.Current clinical development of PI3K pathway inhibitors in glioblastoma.Neuro Oncol,2012;14(7):819-29.

同被引文献31

  • 1杨金成,陈福宝,陈林宝.LY294002对人肾透明细胞腺癌细胞增殖和凋亡的影响[J].宁夏医科大学学报,2013,35(8):877-880. 被引量:3
  • 2李光,金宁,刘明,曲立成,沈腾,李海,张茁,那万里.P53,PTEN,PCNA基因与膀胱癌恶性度的相关性[J].中国老年学杂志,2014,34(3):618-619. 被引量:2
  • 3Datta SR,Brunet A,Greenberg ME.Cellular survival:a play in three Akts.Genes Dev,1999;13(22):2905-2927.
  • 4Carnero A,Blanco-Aparicio C,Renner O,et al.The PTEN/PI3K/AKT signaling pathway in cancer,therapeutic implications.Curr Cancer Drug Targets,2008;8(3):187-198.
  • 5Li X1,Yang Q,Yu H,et al.LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-m TOR pathway.Oncotarget,2014;5(3):788-801.
  • 6Ko YH,Miyake H,Behnsawy HM,et al.Limited Significance of Activated Akt-Mammalian Target of Rapamycin Signaling Pathway in Prostate Cancer Progression.Urol Int,2014;93(2):146-151.
  • 7Agarwal E,Chaudhuri A,Leiphrakpam PD,et al.Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.BMC Cancer,2014;14(1):145.
  • 8Piovan E,Yu J,Tosello V,Herranz D,et al.Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.Cancer Cell,2013;24(6):766-776.
  • 9Bradford LS,Rauh-Hain A,Clark RM,et al.Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/m TOR signaling pathway in endometrial cancer.Gyneco Oncol,2014;133(2):346-352.
  • 10Yap TA,Yan L,Patnaik A,et al.First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol,2011;29(35):4688-4695.

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部